{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T10:41:00Z","timestamp":1767955260317,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"DOI":"10.7759\/cureus.101136","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T09:14:23Z","timestamp":1767950063000},"source":"Crossref","is-referenced-by-count":0,"title":["A Medically Managed Case of Acromegaly: A Case Report"],"prefix":"10.7759","author":[{"given":"Karam","family":"Bdour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaldon","family":"Al-Sarihin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesreen","family":"El Issa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odai","family":"Alwraikat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Albadarneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Al-Asa'd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu'taz","family":"Alwadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Physiology, pituitary hormones","author":"Sadiq NM","year":"2023","unstructured":"Sadiq NM, Tadi P. Physiology, pituitary hormones. StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00003.2011","article-title":"Cellular and molecular specificity of pituitary gland physiology","volume":"92","author":"Perez-Castro C","year":"2012","unstructured":"Perez-Castro C, Renner U, Haedo MR, Stalla GK, Arzt E. Cellular and molecular specificity of pituitary gland physiology. Physiol Rev. 2012, 92:1-38. 10.1152\/physrev.00003.2011","journal-title":"Physiol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson L","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014, 99:3933-51. 10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","article-title":"Gigantism and acromegaly","author":"Bello MO","year":"2025","unstructured":"Bello MO, Garla VV. Gigantism and acromegaly. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28722","article-title":"A comprehensive review of four clinical practice guidelines of acromegaly","volume":"14","author":"Ogedegbe OJ","year":"2022","unstructured":"Ogedegbe OJ, Cheema AY, Khan MA, et al.. A comprehensive review of four clinical practice guidelines of acromegaly. Cureus. 2022, 14:e28722. 10.7759\/cureus.28722","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0754-x","article-title":"Epidemiology of acromegaly: review of population studies","volume":"20","author":"Lavrentaki A","year":"2017","unstructured":"Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017, 20:4-9. 10.1007\/s11102-016-0754-x","journal-title":"Pituitary"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2007.10.002","article-title":"Acromegaly","volume":"37","author":"Ben-Shlomo A","year":"2008","unstructured":"Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am. 2008, 37:101-22. 10.1016\/j.ecl.2007.10.002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1055\/a-1207-1132","article-title":"Hyperprolactinemia in acromegaly is related to prolactin secretion by somatolactotroph tumours","volume":"52","author":"Van Laethem D","year":"2020","unstructured":"Van Laethem D, Michotte A, Cools W, Velkeniers B, Unuane D, Andreescu CE, Bravenboer B. Hyperprolactinemia in acromegaly is related to prolactin secretion by somatolactotroph tumours. Horm Metab Res. 2020, 52:647-53. 10.1055\/a-1207-1132","journal-title":"Horm Metab Res"},{"key":"ref9","article-title":"The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients","volume":"2","author":"Huan C","year":"2015","unstructured":"Huan C, Cui G, Ren Z. The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients. Pak J Pharm Sci. 2015, 2:713-8.","journal-title":"Pak J Pharm Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-1119","article-title":"The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases","volume":"166","author":"Wang M","year":"2012","unstructured":"Wang M, Mou C, Jiang M, et al.. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol. 2012, 166:797-802. 10.1530\/EJE-11-1119","journal-title":"Eur J Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae053","article-title":"Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion","volume":"190","author":"Biagetti B","year":"2024","unstructured":"Biagetti B, Araujo-Castro M, Torre EM, et al.. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion. Eur J Endocrinol. 2024, 190:458-66. 10.1093\/ejendo\/lvae053","journal-title":"Eur J Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1239","article-title":"Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study","volume":"95","author":"Buhk JH","year":"2010","unstructured":"Buhk JH, Jung S, Psychogios MN, et al.. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab. 2010, 95:552-8. 10.1210\/jc.2009-1239","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-3653","article-title":"Let's focus more on regional diversity of acromegaly","volume":"10","author":"St\u00f6rmann S","year":"2022","unstructured":"St\u00f6rmann S. Let's focus more on regional diversity of acromegaly. Ann Transl Med. 2022, 10:848. 10.21037\/atm-22-3653","journal-title":"Ann Transl Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis","volume":"90","author":"Freda PU","year":"2005","unstructured":"Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005, 90:4465-73. 10.1210\/jc.2005-0260","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0129-5","article-title":"Author correction: acromegaly","volume":"5","author":"Colao A","year":"2019","unstructured":"Colao A, Grasso LF, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R. Author correction: acromegaly. Nat Rev Dis Primers. 2019, 5:72. 10.1038\/s41572-019-0129-5","journal-title":"Nat Rev Dis Primers"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.6.7556","article-title":"Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly","volume":"86","author":"Colao A","year":"2001","unstructured":"Colao A, Ferone D, Marzullo P, et al.. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001, 86:2779-86. 10.1210\/jcem.86.6.7556","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8223-16","article-title":"Remarkable shrinkage of a growth hormone (GH)-secreting macroadenoma induced by somatostatin analogue administration: a case report and literature review","volume":"56","author":"Kurahashi K","year":"2017","unstructured":"Kurahashi K, Endo I, Kondo T, et al.. Remarkable shrinkage of a growth hormone (GH)-secreting macroadenoma induced by somatostatin analogue administration: a case report and literature review. Intern Med. 2017, 56:2455-61. 10.2169\/internalmedicine.8223-16","journal-title":"Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345361","article-title":"Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR","volume":"28","author":"Resmini E","year":"2005","unstructured":"Resmini E, Murialdo G, Giusti M, Boschetti M, Minuto F, Ferone D. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. J Endocrinol Invest. 2005, 28:166-9. 10.1007\/BF03345361","journal-title":"J Endocrinol Invest"},{"key":"ref19","article-title":"Primary octreotide LAR therapy in GH-secreting pituitary adenoma","volume":"102","author":"Harinarayan CV","year":"2004","unstructured":"Harinarayan CV. Primary octreotide LAR therapy in GH-secreting pituitary adenoma. J Indian Med Assoc. 2004, 102:260-1.","journal-title":"J Indian Med Assoc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1086000","article-title":"Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration","volume":"117","author":"Ozbek M","year":"2009","unstructured":"Ozbek M, Erdogan M, Akbal E, G\u00f6n\u00fclalan G. Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration. Exp Clin Endocrinol Diabetes. 2009, 117:309-11. 10.1055\/s-0028-1086000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac675","article-title":"Dissecting the in vitro efficacy of octreotide and cabergoline in GH- and GH\/PRL-secreting pituitary tumors","volume":"108","author":"Gatto F","year":"2023","unstructured":"Gatto F, Feelders RA, van Koetsveld PM, et al.. Dissecting the in vitro efficacy of octreotide and cabergoline in GH- and GH\/PRL-secreting pituitary tumors. J Clin Endocrinol Metab. 2023, 108:e98-e109. 10.1210\/clinem\/dgac675","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn E","year":"2017","unstructured":"Kuhn E, Chanson P. Cabergoline in acromegaly. Pituitary. 2017, 20:121-8. 10.1007\/s11102-016-0782-6","journal-title":"Pituitary"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.8.5007","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group","volume":"83","author":"Orme SM","year":"1998","unstructured":"Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998, 83:2730-4. 10.1210\/jcem.83.8.5007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.704496","article-title":"Patient-identified problems and influences associated with diagnostic delay of acromegaly: a nationwide cross-sectional study","volume":"12","author":"Wang K","year":"2021","unstructured":"Wang K, Guo X, Yu S, et al.. Patient-identified problems and influences associated with diagnostic delay of acromegaly: a nationwide cross-sectional study. Front Endocrinol (Lausanne). 2021, 12:704496. 10.3389\/fendo.2021.704496","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref25","article-title":"Acromegaly","author":"Adigun OO","year":"2023","unstructured":"Adigun OO, Nguyen M, Fox TJ, et al.. Acromegaly. StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed S","year":"2009","unstructured":"Melmed S, Colao A, Barkan A, et al.. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009, 94:1509-17. 10.1210\/jc.2008-2421","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients","volume":"83","author":"Abs R","year":"1998","unstructured":"Abs R, Verhelst J, Maiter D, et al.. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998, 83:374-8. 10.1210\/jcem.83.2.4556","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.12996\/gmj.2024.4281","article-title":"Long-term results of cabergoline add-on long-acting somatostatin analogue therapy in acromegaly patients","volume":"35","author":"Yal\u00e7\u0131n MM","year":"2024","unstructured":"Yal\u00e7\u0131n MM, Keser GB, Co\u015fkun M, et al.. Long-term results of cabergoline add-on long-acting somatostatin analogue therapy in acromegaly patients. Gazi Med J. 2024, 35:433-7. 10.12996\/gmj.2024.4281","journal-title":"Gazi Med J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret L","year":"2011","unstructured":"Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011, 96:1327-35. 10.1210\/jc.2010-2443","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0216","article-title":"Clinically silent somatotroph adenomas are common","volume":"165","author":"Wade AN","year":"2011","unstructured":"Wade AN, Baccon J, Grady MS, Judy KD, O'Rourke DM, Snyder PJ. Clinically silent somatotroph adenomas are common. Eur J Endocrinol. 2011, 165:39-44. 10.1530\/EJE-11-0216","journal-title":"Eur J Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450148-a-medically-managed-case-of-acromegaly-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T09:14:24Z","timestamp":1767950064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450148-a-medically-managed-case-of-acromegaly-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.101136","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}